About CSL Vifor
CSL Vifor is a Healthcare company based in Opfikon (Switzerland) founded in 1872, and was acquired by CSL in December 2021. Plasma-derived therapies and vaccines are provided for rare diseases. It operates on a Direct-to-Consumer (D2C) and Professional Services model. CSL Vifor has completed 2 acquisitions, including Inositec and Sanifit. Its chief executive, as recorded, is David Bevan. CSL Vifor offers products and services including Iron Deficiency Therapies and Nephrology Treatments. Its focus areas include Biotechnology and Pharmaceuticals.
Company details
CSL Vifor is recognized as a global leader in therapies for iron deficiency and iron deficiency anemia, with expertise spanning heart failure, kidney disease, and other related conditions. The company is also deeply involved in nephrology, offering a broad portfolio to manage kidney disease complications and improve patient quality of life. Operating in over 100 countries, CSL Vifor is committed to addressing unmet medical needs through innovative pharmaceutical solutions and strategic partnerships. Its history dates back to 1872, and it continues to build on a legacy of precision healthcare.
Products & Services of CSL Vifor
CSL Vifor offers a comprehensive portfolio of products and services, including Iron Deficiency Therapies and Nephrology Treatments.
Therapies for iron deficiency are developed and marketed.
Treatments for kidney disease are provided to patients.
Apps and channels of CSL Vifor
its YouTube channel CSL has 1.72K subscribers and 30 videos.
Videos from CSL Vifor
The most watched videos on CSL Vifor's YouTube channel, CSL (1.72K subscribers). Click a video to play it here.
More on CSL.
Funding Insights of CSL Vifor
- Total Rounds 1
- Investors Count 1
All 1 funding rounds of CSL Vifor with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2017 | Post-IPO | – | – |
2 investors in total: 2 institutional.
Investors in CSL Vifor
CSL Vifor has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include CSL and Ally Bridge Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity and hedge fund investments in healthcare are managed. | ally-bridge.com | Hong Kong, China | ||
CSL is recognized as a global leader in biotechnology. | 1916 | csl.com | Melbourne, Australia |
Investor details for CSL Vifor
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of CSL Vifor
426 people are tracked at CSL Vifor (208 in leadership, 8 in board & advisors, 210 in team).
| Name | Role | Group |
|---|---|---|
David Bevan | CEO | Leadership |
Diego Sacristan | Head Of International; CSL Behring | Leadership |
Matt Tripp | Senior Financial Business Partner | Leadership |
Jordi Pont Arnaiz | Associate Director Sales & Marketing Commercial Spain | Leadership |
Farana Power | Executive Assistant To VP Of Commercial Operations - International Markets And Pandemic | Leadership |
Keely Beck Zipp | Vice President, Immunoglobulins TA & Global Commercial Development Portfolio Planning | Leadership |
Jessica Volk | Director, Strategy & Insight | Leadership |
Laura Schreder | Country & Site Communications Lead - EMEA | Head Of Site Communications Marburg | Leadership |
Paul McKenzie | CEO | Leadership |
Dr. Michael Plater | Senior Director, Global Business Development & Licensing | Leadership |
Joel Hanson | Head Of Project Delivery, US | Leadership |
Chris Larkins | Senior Vice President Operations | Leadership |
Michael Bien | Senior Director Project Management | Leadership |
Elyse Muñoz | Associate Director, Market Intelligence | Leadership |
Leslie Bannon | Enterprise Head Of Alliances | Leadership |
Sue Thorn | Senior Manager, Communications Business Partner For R&d, Vaccines | Leadership |
Philippe Hebert | General Manager | Leadership |
Lukas Limbach | Director, Operations And International Demand Planning | Leadership |
Camilla Shen | Vice President Mid-size EMEA Markets | Leadership |
Kristina Harrison | Director, Pandemic Contracts North America | Leadership |
406 more people are available in the full profile.
Complete people profiles for CSL Vifor
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by CSL Vifor
CSL Vifor has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Inositec and Sanifit.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Therapeutics for soft tissue calcification disorders are developed. | inositec.com | Zurich, Switzerland | 2015 | Nov 2021 | •••• | |
Drugs for cardiovascular, renal, osteoporosis, and oral-dental diseases are developed. | sanifit.com | Palma, Spain | 2007 | Nov 2021 | $231.26M |
Complete acquisition details for CSL Vifor
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Web traffic of CSL Vifor
Websites that share an audience with CSL Vifor (viforpharma.com).
Websites whose visitors overlap most with CSL Vifor. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| galenica.com | 100% | 56.1K | #459,247 | View details | |
| novartis.com | 99% | 948.8K | #58,822 | View details | |
| roche.com | 78% | 1.3M | #42,219 | View details | |
ucb.de | ucb.de | 77% | #3,475,534 | – | |
leo-pharma.co.uk | leo-pharma.co.uk | 75% | #4,369,925 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 11 similar websites and full traffic analytics for CSL Vifor
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 11 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about CSL Vifor
CSL Vifor was founded in 1872 and raised its 1st funding round 145 years after it was founded.
CSL Vifor is headquartered in Opfikon, Switzerland. It is registered at Opfikon, Zurich, Switzerland.
David Bevan is the CEO of CSL Vifor, as recorded in our data.
CSL Vifor is recognized as a global leader in therapies for iron deficiency and iron deficiency anemia, with expertise spanning heart failure, kidney disease, and other related conditions. The company is also deeply involved in nephrology, offering a broad portfolio to manage kidney disease complications and improve patient quality of life. Operating in over 100 countries, CSL Vifor is committed to addressing unmet medical needs through innovative pharmaceutical solutions and strategic partnerships. Its history dates back to 1872, and it continues to build on a legacy of precision healthcare.
CSL Vifor offers Iron Deficiency Therapies and Nephrology Treatments.
CSL Vifor has 2 investors. Key investors include CSL, and Ally Bridge Group.
CSL Vifor operates through Csl Vifor.
Yes. CSL Vifor was acquired by CSL in December 2021.